Literature DB >> 10733174

Lung surfactant protein A provides a route of entry for respiratory syncytial virus into host cells.

T P Hickling1, R Malhotra, H Bright, W McDowell, E D Blair, R B Sim.   

Abstract

Lung surfactant protein A (SP-A) has a central role in host defense mediated by the interaction of surface carbohydrates of inhaled pathogens with the lectin domains of SP-A. Respiratory syncytial virus (RSV), the most important viral pathogen of neonates and infants, encodes a highly glycosylated attachment protein, G. Binding studies were performed with G-protein from RSV (human, A2 strain) and human SP-A. The effect of SP-A on the interaction between RSV and host cells was determined by two methods: an infectivity study with monolayers of Hep-2C cells and by interleukin-8 (IL-8) release from buffy coat (BC) cells. SP-A binds to RSV G-protein in a concentration-dependent manner that is inhibitable by both ethylenediamine tetraacetic acid (EDTA) and mannan, indicating that binding is through the carbohydrate recognition domain of the SP-A and a carbohydrate moiety of the G-protein. The level of RSV infection of Hep-2C cells increases with increasing concentrations of SP-A. The amount of IL-8 released by BC cells in the presence of RSV is increased with SP-A concentrations of 2.9 microg/mL or greater. Our results show that SP-A enhances the attachment of RSV and subsequent entry into host cells. The effect of SP-A on viral uptake by epithelial cells and macrophage may determine both innate and adaptive immune responses to RSV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733174     DOI: 10.1089/vim.2000.13.125

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  24 in total

1.  Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity.

Authors:  Roberta L Crim; Susette A Audet; Steven A Feldman; Howard S Mostowski; Judy A Beeler
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

Review 2.  Importance of Virus Characteristics in Respiratory Syncytial Virus-Induced Disease.

Authors:  Homero San-Juan-Vergara; Mark E Peeples
Journal:  Immunol Allergy Clin North Am       Date:  2019-05-22       Impact factor: 3.479

Review 3.  Macrophage immunoregulatory pathways in tuberculosis.

Authors:  Murugesan V S Rajaram; Bin Ni; Claire E Dodd; Larry S Schlesinger
Journal:  Semin Immunol       Date:  2014-10-30       Impact factor: 11.130

4.  Identification and characterization of human surfactant protein A binding protein of Mycoplasma pneumoniae.

Authors:  T R Kannan; D Provenzano; J R Wright; J B Baseman
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

Review 5.  Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.

Authors:  Asuncion Mejias; Cristina Garcia-Maurino; Rosa Rodriguez-Fernandez; Mark E Peeples; Octavio Ramilo
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

Review 6.  The immune response to respiratory syncytial virus infection: friend or foe?

Authors:  Robert C Welliver
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

Review 7.  Structure and function of respiratory syncytial virus surface glycoproteins.

Authors:  Jason S McLellan; William C Ray; Mark E Peeples
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

8.  Differences in the alveolar macrophage proteome in transgenic mice expressing human SP-A1 and SP-A2.

Authors:  David S Phelps; Todd M Umstead; Patricia Silveyra; Sanmei Hu; Guirong Wang; Joanna Floros
Journal:  J Proteom Genom Res       Date:  2013-04-01

Review 9.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

Review 10.  The journey to a respiratory syncytial virus vaccine.

Authors:  Asuncion Mejias; Rosa Rodríguez-Fernández; Silvia Oliva; Mark E Peeples; Octavio Ramilo
Journal:  Ann Allergy Asthma Immunol       Date:  2020-03-23       Impact factor: 6.347

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.